Clearly, glioma samples with high expression of FXYD6 had lower stromascore, immunescore, and estimatescore (Figure 3C), which indicated FXYD6 expression was negatively correlated with the amout of immune and stromal proportion. The gene discussed is FXYD6; the disease is central nervous system cancer.